Japan
· Delayed Price · Currency is JPY Healios K.K. Company Description
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States.
The company develops HLCM051, which is preparing for phase 3 clinical trial, as well as preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is in phase 2/3 and phase 3 clinical trial to treat ischemic stroke; and HLCM051, which is in phase 2 clinical trial to treat trauma.
It also develops HLCR011, which is in phase 1/2 clinical trial for the treatment of retinal pigmen epithelium and age-related macular degeneration; and HLCN061, which is in discovery and preclinical trial for treating solid tumors.
The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013.
Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
| Country | Japan |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Tadahisa S. Kagimoto |
Contact Details
Address: Hibiya Mitsui Tower, WORK STYLING Tokyo, 100-0006 Japan | |
| Website | healios.co.jp |
Stock Details
| Ticker Symbol | 4593 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3835100003 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Tadahisa S. Kagimoto | Chief Executive Officer |
| Richard P. Kincaid | Chief Financial Officer |